---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-24-059364"
form_type: "8-K"
ticker: "IOBTQ"
cik: "0001865494"
company_name: "IO Biotech, Inc."
filed_at: "2024-03-05T23:59:59+00:00"
generated_at: "2026-06-05T04:12:01.509490+00:00"
event_type: "earnings"
sentiment: "neutral"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# IO Biotech Q4 net loss $26.2M; Phase 3 melanoma trial enrollment complete, interim ORR analysis expected Q3 2024

## Summary
- Net loss $26.2M in Q4 2023 vs $20.1M YoY; R&D expenses $21.8M on Phase 3 trial costs.
- Cash $143.2M at Dec 31, 2023; operational runway projected into Q4 2025.
- Completed enrollment of 380 patients in pivotal Phase 3 trial of IO102-IO103 + Keytruda in advanced melanoma.
- Planned interim ORR analysis from first 225 patients expected in Q3 2024; PFS primary endpoint anticipated H2 2025.
- First patient dosed in Phase 2 basket trial of IO102-IO103 neoadjuvant/adjuvant in resectable solid tumors.

## SEC filing metadata
- accession: 0001193125-24-059364
- form_type: 8-K
- ticker: IOBTQ
- cik: 0001865494
- company_name: IO Biotech, Inc.
- filed_at: 2024-03-05T23:59:59+00:00
- event_type: earnings
- sentiment: neutral
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 2.02, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1865494/000119312524059364/0001193125-24-059364-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1865494/000119312524059364/d747385d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-24-059364
- JSON: https://secwatch.observer/filing/0001193125-24-059364.json
- Plain text: https://secwatch.observer/filing/0001193125-24-059364.txt

## Key facts
- Earnings Releases
  IO Biotech, Inc. reported three months ended December 31, 2023 results: net income $26.2 million.
  - Period: three months ended December 31, 2023
  - Net income: $26.2 million
  - Result: reported results
  source text: Net loss for the three months ended December 31, 2023, was $26.2 million, compared to $20.1 million for the three months ended December 31, 2022.
  evidence_url: https://www.sec.gov/Archives/edgar/data/1865494/000119312524059364/0001193125-24-059364-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.